EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from EV71 virus-like particles

A virus-like and particle technology, applied in the field of biomedicine, can solve the problems of restricting large-scale production requirements, complex VLP purification process, and high requirements for culture conditions, achieving reasonable spatial folding, facilitating industrial production, and simplifying the screening process.

Inactive Publication Date: 2011-08-17
张定梅 +3
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since insect cells are mainly used to prepare VLPs at present, the culture conditions are relatively high; and because of intracellular expression, the VLP purification process is complicated, which limits the large-scale production requirements; and another major defect of the baculovirus-insect cell system It is the production of baculovirus particles and other pollutants that obviously affect the vaccine effect. Since the baculovirus particles are difficult to separate from the prepared VLP, the prepared VLP needs to be chemically inactivated and other measures used in clinical practice. These treatments may cause Affects the quality of the prepared VLP

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from EV71 virus-like particles
  • EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from EV71 virus-like particles
  • EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from EV71 virus-like particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0034] Embodiment Preparation of EV71 virus-like particles of the present invention

[0035] For the molecular biology experimental methods such as RT-PCR, restriction enzyme digestion and ligation used in the present invention, please refer to the second edition of "Molecular Cloning".

[0036] The basic materials for preparing EV71 virus-like particles of the present invention include: EV71 virus P1 gene, 3CD gene, pGAPZαA plasmid (product of Invitrogen, USA), and yeast strain SMD1168 (product of Invitrogen, USA).

[0037] 1. P1 gene, 3CD gene cloning

[0038] 1. First-strand cDNA preparation

[0039] The EV71 viral RNA was reverse-transcribed into cDNA with the Shanghai Sangon Recombinant Avian Myeloblastosis Virus Reverse Transcriptase (AMV) First-Strand cDNA Reverse Transcription Kit.

[0040] 2. Primer Design

[0041] The P1 gene and 3CD gene primers were designed with the help of Primer Premier 5.0 software, and were synthesized by Shanghai Sangong. The underline is ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from the EV71 virus-like particles. The EV71 virus-like particles are prepared according to the following steps: (1) constructing recombinant plasmid: respectively connecting pGAPZ alpha A plasmid with P1 protein gene of intestinal EV71 virus and 3CD protease gene to construct P1-pGAPZ alpha A and 3CD-pGAPZ alpha A recombinant plasmid; (2) transferring the recombinant plasmid to expression bacterial strains: sequentially transferring the recombinant plasmid to Pichia pastoris SMD1168 expression bacterial strains to obtain P1-pGAPZ alpha A-3CD-pGAPZ alpha A-SMD1168 recombinant expression strains; and (3) culturing thallus and purifying the EV71 virus-like particles: culturing the Pichia pastoris recombinant expression bacterial strains, centrifugalizing to separate supernate, and carrying out sucrose density gradient centrifugation on precipitation of the supernate after ultracentrifugation, thus obtaining the EV71 virus-like particles. In the invention, the EV71 virus-like particles are easy to obtain through thallus culture, have good stability, are easy to purify and suitable for preparing vaccine, and are convenient for industrial production.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an EV71 virus-like particle and a hand, foot and mouth disease vaccine prepared therefrom. Background technique [0002] Since 1957, hand, foot and mouth disease has broken out in many countries in the world, especially since the 1990s, it has become increasingly rampant in the Asia-Pacific region. Since 2007, there has been an outbreak of hand, foot and mouth disease in mainland China. By the end of September 2010, more than 3 million children have been reported to be infected with hand, foot and mouth disease, which seriously threatens the health and life safety of children. The pathogens of HFMD are mainly picornaviruses, members of the Enterovirus genus, mainly Coxsakie A group 16 (Coxsakie A 16 , CoxA16) and enterovirus 71 (enterovirus 71, EV71), wherein EV71 virus is the main pathogen that causes neurological complications and death cases. [0003] At present, there i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/04A61K39/125A61P31/14
Inventor 张定梅陆家海曹开源黎孟枫
Owner 张定梅
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products